We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.65 | 2.30 | 3.00 | - | 0.00 | 13:55:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 5.03M | -2.44M | -0.0083 | -3.19 | 7.82M |
Date | Subject | Author | Discuss |
---|---|---|---|
15/9/2024 09:12 | Jibberish, no change. | emigna2020 | |
15/9/2024 09:04 | If Carlberg did deluded…. | barry evans | |
15/9/2024 08:55 | wasjobber Good man ,ignore the M`Icke gang of scum. | emigna2020 | |
15/9/2024 08:54 | wasjobber, thank you. I think it is important to explain that essentially there are two acquisition modes that mass specs use for proteomics data collection. DDA (Data Dependant Acquisition) mode and DIA (Data Independent Acquisition) mode. TMT reagents are only used for the DDA mode. Now Proteome Sciences have designed, patented and produced the first set of 6-plexDIA reagents for DIA mode, this now addresses a whole NEW MARKET of mass spec proteomics customers. I believe the existing large base of DIA mode customers will be keen to use Proteome Sciences new 6-plexDIA reagents, with the prospects of the reagents rapidly expanding to 26-plex and probably more. It will be interesting to see who Proteome Sciences sign a license deal with soon, as growth in the DIA user market will be rapid, from an existing large base of customers who are keen to multiplex their mass spec proteomics measurements. | pools2 | |
15/9/2024 08:29 | You mean #93060 presumably | bluemango | |
14/9/2024 20:27 | >93059 - as in Chief Executive | suffolkhath | |
14/9/2024 16:53 | Reliably unreliable - that you can rely on. | monte1 | |
14/9/2024 16:45 | "reliably" | jeffian | |
14/9/2024 16:22 | If you actually read and understand the details of yesterdays RNS properly, the future looks better than ever. Proteome Sciences are about to grab the larger part of the mass spec proteomics tagging market by offering DIA users their new plex-DIA reagents, up to at least 26-plex. This is impressive. DIA users are waiting for higher plexing reagents. With current reagents DIA users can only perform up to 3-plex measurements. Proteome Sciences offering 6-plex intially and then up to at least 26-plexDIA is a massive leap forward and something most if not all DIA users will want to use! This is a new large untouched market for PRM's new plex-DIA reagents and it looks like they're going 'full on' to dominate it, much like the TMT-DDA market. Add to that the new 32/35-plex TMTpro reagents now being shipped to eager customers, revenues will leap. Add to that the new clinical biomarkers services contracts, some license fees, milestone fees and further running royalties, Proteome Sciences will be comfortably in profit. Then there is the Alzheimers Disease IP and Cancer pathway IP. Watch this space closely! STRONG BUY | wasjobber | |
14/9/2024 16:17 | It's not over yet! PRM still have a business and IP that has some value. The immediate issue might be cash to get them through, nonetheless, this is a shocking disappointment, how did everything go so wrong ?. | 049balt | |
13/9/2024 23:23 | Tbf it actually bit the dust around 20 years ago, avatars simply wouldn’t accept it and increased their losses time and time again for a good decade or more since. | barry evans | |
13/9/2024 21:53 | Another one bites the dust | suffolkhath | |
13/9/2024 11:48 | I understand that Diane Abbott is crunching the numbers. | monte1 | |
13/9/2024 11:20 | Depressing when they can't even get the punctuation on the press release correct.. "In addition, the US lab in San Diego, has delivered its first projects.." I'm just hoping they are better with numbers ... eventually. | small crow | |
13/9/2024 11:11 | Hand Massager Market size is estimated to register a CAGR of around 3.8% between 2024 & 2032. To know more, visit :- Key players are :- Aarogya Mandir Lifepro Comfier Massager Factory Cotsoco | elpirata | |
13/9/2024 10:33 | There re 3 sets of different 32plex reagents, and these can be used in such a way as to give 96plex. Together with 6 calibration channels as well. That is what is getting the industry excited. | goatherd | |
13/9/2024 10:31 | I am sure I am not the only avatar to note the significance of the date of this RNS. vbrs J Voorhees | barry evans | |
13/9/2024 10:28 | Thanks gnnmartin, I recon on a good day at the right auction house my notepad could fetch more than all the sets of 20-plexDIA reagents put together. | barry evans | |
13/9/2024 10:01 | Barry, gosh, what a long memory you have. As I wrote above, it was the hiring of Dr S. in 2021 that finally persuaded me to buy some PRM (on 24/4/2021). | gnnmartin | |
13/9/2024 09:59 | Its probably Diggle posting in desperation, what between this pos & obd race to oblivion he needs snookers to get his money back | elpirata | |
13/9/2024 09:22 | Proteome Sciences to make a set of 20-plexDIA reagents. This is remarkable. This is massive news for the proteomics market and a game changer for DIA measurements, which are currently limited to just 3-plex. | pools2 | |
13/9/2024 09:16 | Oh hello gross profit margin down from 50% to 10% so what else have they stuck in cost of sales? trade & receivables down by 67% but no change in admin costs Cash down by almost half to £1.2m Theres a cash crunch coming Q1 2025 if not before STRONG SELL | elpirata | |
13/9/2024 08:43 | Morning G - long time no ‘see’. Who would have thunk it eh? A bit to go to get to the ‘next stop 10p then 30p’ never mind the goatfabled £53 And yet still being labelled a ‘strong buy’ from the braying avatar pools2/wasjobber even before todays 17% drop. As for Mariola - it seems pretty clear to me (0), whether that was down to her or the duff hand she was dealt is another matter. | monte1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions